Evogene Announces Collaboration With Google Cloud To Pioneer Generative AI Foundation Model For Novel Small Molecule Design, Leveraging Evogene's Deep Expertise In Computational Predictive Biology And Google Cloud's Leadership In AI And Machine Learning
Evogene Announces Collaboration With Google Cloud To Pioneer Generative AI Foundation Model For Novel Small Molecule Design, Leveraging Evogene's Deep Expertise In Computational Predictive Biology And Google Cloud's Leadership In AI And Machine Learning
The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based products
合作關係具有促進基於生命科學的產品小分子創新的力量
REHOVOT, Israel, Oct. 31, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene's ChemPass AI tech-engine to new levels of innovation. ChemPass AI is a computational technology platform that directs and accelerates the discovery and development of novel products based on small molecules. This groundbreaking initiative seeks to advance the discovery and development of novel small molecules for drug development, sustainable crop protection, and other innovative products across a wide range of life-science industries.
以色列雷霍沃特，2024年10月31日 / PRNewswire / - Evogene Ltd.（納斯達克：EVGN）（TASE：EVGN），一家領先的計算生物學公司，致力於革新基於生命科學的產品發現和開發，今天宣佈與Google Cloud合作，開發一款開創性的基礎模型，用於生成小分子全新設計，將Evogene的ChemPass人工智能技術引擎推向創新新高。ChemPass AI是一個計算技術平台，用於指導和加速基於小分子的新產品發現和開發。這一突破性舉措旨在推動用於藥物研發、可持續農業保護以及其他創新產品的新型小分子的發現和開發，涵蓋生命科學產業的廣泛領域。
譯文內容由第三人軟體翻譯。
